Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II studyResearch in context

Summary: Background: Toripalimab, a novel PD-1 antibody, is approved for treatment of multiple solid tumors; however, its neoadjuvant use with chemotherapy for triple-negative breast cancer (TNBC) remains unevaluated. Additionally, induction chemotherapy followed by de-escalation of neoadjuvant imm...

Full description

Bibliographic Details

Published in:	EClinicalMedicine
Main Authors:	Min He, Shuang Hao, LinXiaoxi Ma, BingQiu Xiu, BenLong Yang, ZeHao Wang, JingYan Xue, YaYun Chi, Min Xiong, JiaJian Chen, XiaoYan Huang, XiYu Liu, SongYang Wu, Qin Xiao, Yan Huang, RuoHong Shui, AYong Cao, JunJie Li, GenHong Di, WenTao Yang, Xin Hu, GuangYu Liu, KeDa Yu, YiZhou Jiang, ZhongHua Wang, ZhiMing Shao, Jiong Wu
Format:	Article
Language:	English
Published:	Elsevier 2024-08-01
Subjects:	Triple-negative breast cancer Neoadjuvant therapy Immune checkpoint inhibitor Induction treatment De-escalation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537024002797